Free tool · No account
Clinical trials for bladder cancer
Bladder cancer trials differ between early, non-muscle-invasive disease and advanced disease, with immunotherapy and antibody-drug conjugates prominent in the advanced setting.
402 recruiting trials. Showing a sample.
- recruitingNANCT07225205
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
Radical cystectomy is the standard of care for muscle invasive bladder cancer, however despite advances, it is still associated with high morbidity. Many complications may be driven by dehydration and it is unclear if a home intravenous fluid (IVF) infusion program post-operat...
Sponsored by Johns Hopkins UniversityFull details on ClinicalTrials.gov → - recruitingPhase 3NCT07218380
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in combination with enfortumab vedotin an...
Sponsored by Eli Lilly and CompanyFull details on ClinicalTrials.gov → - recruitingNCT07545694
Study on the Effects of Drugs That Modulate the Endocannabinoid System on Spontaneous and Induced Contractility of the Human Detrusor Muscle
The goal of this observational, in vitro study is to evaluate the effects of drugs that modulate the endocannabinoid system on spontaneous and neuronally induced contractility of the human detrusor. The study will include adult patients undergoing elective radical cystectomy f...
Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCSFull details on ClinicalTrials.gov → - recruitingPhase 2, Phase 3NCT07106762
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
A Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy
Sponsored by Bristol-Myers SquibbFull details on ClinicalTrials.gov → - recruitingNCT05415631
Augmented Bladder Tumor Detection Using Real Time Based Artificial Intelligence
Today the standard for the diagnosis and monitoring of bladder tumors is bladder endoscopy. The performance of this exam is not perfect. With this work, based on artificial intelligence, the investigators wish to combine endoscopy with a complementary diagnostic tool in order ...
Sponsored by Centre Hospitalier Universitaire, AmiensFull details on ClinicalTrials.gov → - recruitingPhase 2NCT05879653
Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)
This study is designed to assess the efficacy and safety of induction therapy with MK-3475 and ASG-22CE and radiation therapy with MK-3475 in patients with cT2-4aN0M0 muscle invasive bladder cancer who are unfit for or refuse radical cystectomy.
Sponsored by Kyoto University HospitalFull details on ClinicalTrials.gov → - recruitingNANCT04368702
CONFIRM: Magnetic Resonance Guided Radiation Therapy
This research is being done to determine the safety and feasibility of using a type of radiation guided by magnetic resonance imaging (MRI) and chemotherapy to treat patients with gastric and breast cancer. The name of the radiation machine involved in this study is the MRIdia...
Sponsored by Brigham and Women's HospitalFull details on ClinicalTrials.gov → - recruitingNCT07726602
Tumor-informed ctDNA in Muscle-invasive Bladder Cancer for Evaluation of Residual/Recurrent Disease - the TiMBER Trial
This study investigates the feasibility of the Labcorp Plasma Detect, which is an assay (test) that looks for circulating tumor DNA (ctDNA) in patients who have muscle-invasive (MI) urothelial carcinoma (also known as MI bladder cancer, MIBC). During this study, tissue, blood ...
Sponsored by OHSU Knight Cancer InstituteFull details on ClinicalTrials.gov → - recruitingPhase 1, Phase 2NCT05706129
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
The main purpose of Part A of the study is to evaluate safety, tolerability and tracer uptake after a single intravenous (IV) administration of \[68Ga\]Ga-DPI-4452 for each tumor type such as clear cell renal cell cancer (ccRCC), pancreatic ductal adenocarcinoma (PDAC), and co...
Sponsored by Lumara Bio Oncologics GmbHFull details on ClinicalTrials.gov → - recruitingNANCT05739968
Impacts and Testing of the "Multi-domains Active-living Program" in Operable Non-Muscle Invasive Bladder Cancer Patients
Among bladder cancer, the majority of them (70%) are non-muscle-invasive bladder cancer (NMIBC). The survival time is even longer in NMIBC. Patients with NMIBC receive surgery or transurethral resection of bladder tumor (TURBT). However, patients with NMIBC need to receive a t...
Sponsored by National Taiwan University HospitalFull details on ClinicalTrials.gov →
Data from ClinicalTrials.gov, retrieved 2026-08-08. These are trials worth asking your care team about, not a determination that anyone qualifies. Eligibility is decided by the trial's own doctors.
Refine for your situation
Add whatever you know: an age, a city, a mutation from a pathology report. We'll narrow the list to trials that fit. Describe it in your own words.
Trials for other conditions
What we will never do with your records
This generator runs without an account, and KeptWell itself makes the same promises to every family, regardless of plan or price.
- We won't sell your data.
- Not to advertisers, not to data brokers, not to insurers, not to pharma, not to anyone, in any form, ever.
- We won't train AI models on your records.
- Anthropic (whose Claude model powers KeptWell) is contractually prohibited from training on anything we send them, under a signed Business Associate Agreement.
- We won't lock you in.
- You can export everything in your circle as a ZIP at any time. Cancellation is one click.
Common questions
- Is this bladder cancer trial finder really free?
- Yes. You describe the situation, we search ClinicalTrials.gov and show what matches. No account, no payment, no email required. Nothing you type is saved.
- Does showing up here mean the patient qualifies?
- No. These are trials worth asking your care team about. Every trial has detailed eligibility criteria that the trial's own doctors evaluate, and many depend on test results and treatment history that only your medical team knows in full.
- How current is this list?
- The trials come directly from ClinicalTrials.gov and are refreshed daily. Each result links to the full, live study record, and the finder above always runs a fresh search when you use it.
- What should I do with a trial that looks promising?
- Bring it to your oncologist or care team, and mention the NCT number (the ID that starts with NCT). They can tell you whether it is a genuine fit and refer you to the trial site.
Found trials worth discussing? Keep them next to the records.
The next step is a conversation with the care team, and that goes better when the scans, labs, and trial details live in one place everyone in the family can see. That's what KeptWell is: the binder, but it understands what's inside.
Get started
No password. We'll email you a sign-in link — it works whether you're new here or already have an account.